AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Raymond James raised the firm’s price target on Gilead (GILD) to $103 from $95 and keeps an Outperform rating on the shares. The firm called Gilead’s Q3 earnings beat “solid,” citing strong continued ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

LB Denzel Perryman, OL Trey Pipkins III, former Chargers outside linebacker Larry English and many volunteers gathered at U.S ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

Born in Lincolnville, South Carolina, Dr. Pernessa Seele has dedicated over 37 years to bridging the gap between faith and ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Gilead Sciences, Inc. (GILD) is currently at $97.23, up $5.54 or 6.04% --Would be highest close since April 27, 2016, when it closed at $100.72 --On pace for largest percent increase since June 20, ...